Evidence map›Paper›PMID 26556936›Full record

ArticlePublic health reports (Washington, D.C. : 1974)

Preventive Aspirin and Other Antiplatelet Medication Use Among U.S. Adults Aged ≥ 40 Years: Data from the National Health and Nutrition Examination Survey, 2011-2012.

Qiuping Gu, Charles F Dillon, Mark S Eberhardt, Jacqueline D Wright, Vicki L Burt

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health reports (Washington, D.C. : 1974). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. A Survey of Aspirin Knowledge Among the General Public.Journal of general internal medicine · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Qiuping GuCenters for Disease Control and Prevention, National Center for Health Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, MD.
Charles F DillonCenters for Disease Control and Prevention, National Center for Health Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, MD.
Mark S EberhardtCenters for Disease Control and Prevention, National Center for Health Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, MD.
Jacqueline D WrightNational Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD.
Vicki L BurtCenters for Disease Control and Prevention, National Center for Health Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, MD.
Centers for Disease Control and Prevention · USNational Center for Health Statistics · USNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe estimated the prevalence of preventive aspirin and/or other antiplatelet medication use and the dosage of aspirin use in the U.S. adult population.

methodsWe conducted cross-sectional analyses of a representative sample (n=3,599) of U.S. adults aged ≥ 40 years from the National Health and Nutrition Examination Survey, 2011-2012.

resultsIn 2011-2012, one-third of U.S. adults aged ≥ 40 years reported taking preventive aspirin and/or other antiplatelet medications, 97% of whom indicated preventive aspirin use. Preventive aspirin use increased with age (from 11% of those aged 40-49 years to 54% of those ≥ 80 years of age, p<0.001). Non-Hispanic white (35%) and black (30%) adults were more likely to take preventive aspirin than non-Hispanic Asian (20%, p<0.001) and Hispanic (22%, p=0.013) adults. Adults with, compared with those without health insurance, and adults with ≥ 2 doctor visits in the past year, diagnosed diabetes, hypertension, or high cholesterol were twice as likely to take preventive aspirin. Among those with cardiovascular disease, 76% reported taking preventive aspirin and/or other antiplatelet medications, of whom 91% were taking preventive aspirin. Among adults without cardiovascular disease, 28% reported taking preventive aspirin. Adherence rates to medically recommended aspirin use were 82% overall, 91% for secondary prevention, and 79% for primary prevention. Among current preventive aspirin users, 70% were taking 81 milligrams (mg) of aspirin daily and 13% were taking 325 mg of aspirin daily.

conclusionThe vast majority of antiplatelet therapy is preventive aspirin use. A health-care provider's recommendation to take preventive aspirin is an important determinant of current preventive aspirin use.

Indexed as

Drug Utilization ReviewAdultAgedAged, 80 and overAge FactorsAspirinCross-Sectional StudiesHumansMiddle AgedPlatelet Aggregation InhibitorsPrimary PreventionSecondary PreventionSurveys and QuestionnairesUnited StatesAspirinPlatelet Aggregation Inhibitors

Identifiers

PMID26556936
PMCPMC4612173
OpenAlexW2418647883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.